BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  Policy

  Medicare Likely to Negotiate Prices for Obesity Drugs in Next Few Years: CBO

  A new analysis from the Congressional Budget Office predicts that Novo Nordisk’s semaglutide will likely be subjected to Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.

  March 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Bayer Eliminates Nearly Half of Its Executive Positions in Major Overhaul

  As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes for its executives.

  March 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Mirador Launches with $400M in Funding, Targets Precision Medicines

  Mirador Therapeutics emerged from stealth Thursday with financing from ARCH Venture Partners and Sanofi, among others, to provide precision medicines for inflammatory and fibrotic diseases.

  March 21, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Biotech Beach

  Capstan Secures $175M Oversubscribed Series B with Backing from J&J, Bayer and BMS

  Capstan Therapeutics is looking to move its CAR-T cell candidate forward after securing financing from pharma venture arms and VC firms.

  March 21, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Merck, Others Look to Immunotherapy Combos as Next Frontier in Oncology

  Drugmakers are testing a variety of biologics and small molecules in conjunction with therapies aimed at modulating the immune system to target and destroy cancer cells.

  March 21, 2024

   · 

  4 min read

   · 

  Sunitha Chari
• 

  Employer Resources

  In an Evolving Market, HR Leaders Balance Business Needs with Employee Engagement

  BioSpace spoke to HR leaders about how they have been supporting companies navigating a challenging economy while meeting the needs of the workforces they support.

  March 21, 2024

   · 

  7 min read

   · 

  Chantal Dresner
• 

  FDA

  Idorsia Wins FDA Approval in Hypertension Months After J&J Returned Rights to Drug

  Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.

  March 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Merck’s Keytruda Continues NSCLC Losing Streak with Phase III Flop

  Keytruda, when used with AstraZeneca’s Lynparza, did not significantly improve overall and progression-free survival in specific patients with metastatic non-squamous non-small cell lung cancer.

  March 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Money Talk: Salary Trends and Raises

  This week, we’re talking money! Following the release of BioSpace’s ⁠2024 Salary Report⁠, we discuss salary trends and how they are impacting the biopharma workforce.

  March 21, 2024

   · 

  1 min read

   · 

  BioSpace Insights
• 

  Drug Development

  Opinion: ALS Is Not a Singular Disease. Stop Treating It Like One

  Imagine testing a really good drug for HER2+ breast cancer in someone with liver cancer. Would it be any surprise when that drug fails?

  March 21, 2024

   · 

  5 min read

   · 

  Bernie Zipprich